Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world US study

被引:2
|
作者
Huang, Daniel Q. [1 ,2 ]
Tran, Sally [3 ]
Barnett, Scott [3 ]
Zou, Biyao [3 ]
Yeo, Yee Hui [4 ]
Cheung, Ramsey [3 ,5 ]
Nguyen, Mindie H. [3 ,6 ]
机构
[1] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[2] Natl Univ Hlth Syst, Div Gastroenterol & Hepatol, Singapore, Singapore
[3] Stanford Univ, Med Ctr, Div Gastroenterol & Hepatol, 780 Welch Rd, Palo Alto, CA 94304 USA
[4] Cedars Sinai Med Ctr, Div Gen Internal Med, Los Angeles, CA USA
[5] Vet Affairs Palo Alto Healthcare Syst, Div Gastroenterol & Hepatol, Palo Alto, CA USA
[6] Stanford Univ, Dept Epidemiol & Populat Hlth, Palo Alto, CA 94304 USA
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
HCC surveillance; Diabetes mellitus; Platelet count; Thrombocytopenia; Non-cirrhotic; Natural history; Liver cancer; Hepatoma; Screening; Steatosis; FATTY LIVER-DISEASE; CANCER; PREVALENCE; RISK;
D O I
10.1007/s12072-023-10616-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background A substantial proportion of patients with nonalcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC) do not have cirrhosis. Data regarding the incidence and predictors of HCC development in NAFLD without cirrhosis are limited. We conducted a large, national study of NAFLD patients without documented cirrhosis to examine the incidence and predictors for HCC development.Methods This retrospective study included 751,603 NAFLD patients (54% female) without documented cirrhosis derived from the deidentified Optum Clinformatics (R) Data Mart Database. Patients with cirrhosis, platelets < 120,000/mu L or FIB-4 values > 2.67 were excluded.Results The mean age was 53.7 +/- 15.0 years, 45.9% were male, 39.5% had diabetes, 57.6% were White, 18.4% Hispanic, 8.2% Black and 4.9% were Asian. The mean platelet count was 264,000 +/- 72,000/mu L, and 96.3% of patients had a FIB-4 < 1.30. Over 1,686,607 person-years of follow-up, there were 76 incident cases of HCC, resulting in an HCC incidence rate of 0.05 per 1000 person-years. There was a higher HCC incidence rate among patients with platelets <= 150,000/<mu>L, versus those with platelets > 150,000/mu L (0.23 per 1000 person-years, vs. 0.04 per 1000 person-years, p = 0.02) but not in subgroup analyses for age, sex, race/ethnicity or diabetes. Using multivariable Cox proportional hazards model adjusted multiple confounders, platelet count <= 150,000/mu L remained an independent predictor of HCC development (adjusted HR 5.80, 95% CI 1.67-20.1, p = 0.006).Conclusion HCC incidence in NAFLD without documented cirrhosis was below the threshold for cost-effective HCC surveillance in overall and multiple subgroup analyses. Platelet count < 150,000/mu L may be a useful predictor of HCC development in this population.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 50 条
  • [31] Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world US patients, 2003-2021
    Tran, Sally
    Zou, Biyao
    Lee, Keeseok
    Kam, Leslie
    Yeo, Yeehui
    Henry, Linda
    Cheung, Ramsey
    Nguyen, Mindie H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 212 - 223
  • [32] Incidence and Predictors of Synchronous Bone Metastasis in Newly Diagnosed Differentiated Thyroid Cancer: A Real-World Population-Based Study
    Qi, Lin
    Zhang, Wenchao
    Ren, Xiaolei
    Xu, Ruiling
    Liu, Chaoqian
    Tu, Chao
    Li, Zhihong
    FRONTIERS IN SURGERY, 2022, 9
  • [33] Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
    Ganne-Carrie, Nathalie
    Nahon, Pierre
    Chaffaut, Cendrine
    N'Kontchou, Gisele
    Layese, Richard
    Audureau, Etienne
    Chevret, Sylvie
    JHEP REPORTS, 2021, 3 (03)
  • [34] Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study
    Doyle, Adam
    Marsh, Philip
    Gill, Raghubinder
    Rodov, Marcia
    Mohsen, Waled
    Varma, Poornima
    Hong, Thai
    Strasser, Simone I.
    Bell, Sally
    Ryan, Marno
    Nicoll, Amanda
    Lubel, John
    Gow, Paul J.
    Fink, Michael Anthony
    Roberts, Stuart
    Kemp, William
    Kronborg, Ian
    Arachchi, Niranjan
    Knight, Virginia
    Dev, Anouk
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (08) : 979 - 985
  • [35] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Yue Han
    Guang Cao
    Bin Sun
    Jian Wang
    Dong Yan
    Haifeng Xu
    Qinsheng Shi
    Zechuan Liu
    Weihua Zhi
    Liang Xu
    Bojun Liu
    Yinghua Zou
    BMC Gastroenterology, 21
  • [36] Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study
    Hanzel, Jurij
    Bozic, Tajda Kosir
    Stabuc, Borut
    Jansa, Rado
    RADIOLOGY AND ONCOLOGY, 2020, 54 (02) : 233 - 236
  • [37] Lenvatinib for the treatment of hepatocellular carcinoma—a real-world multicenter Australian cohort study
    Kurvi Patwala
    David Stephen Prince
    Yael Celermajer
    Waafiqa Alam
    Eldho Paul
    Simone Irene Strasser
    Geoffrey William McCaughan
    Paul Gow
    Siddharth Sood
    Elise Murphy
    Stuart Roberts
    Elliot Freeman
    Elizabeth Stratton
    Scott Anthony Davison
    Miriam Tania Levy
    McCawley Clark-Dickson
    Vi Nguyen
    Sally Bell
    Amanda Nicoll
    Ashley Bloom
    Alice Unah Lee
    Marno Ryan
    Jessica Howell
    Zina Valaydon
    Alexandra Mack
    Ken Liu
    Anouk Dev
    Hepatology International, 2022, 16 : 1170 - 1178
  • [38] Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
    Han, Yue
    Cao, Guang
    Sun, Bin
    Wang, Jian
    Yan, Dong
    Xu, Haifeng
    Shi, Qinsheng
    Liu, Zechuan
    Zhi, Weihua
    Xu, Liang
    Liu, Bojun
    Zou, Yinghua
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [39] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
    Chan, Stephen Lam
    Ryu, Min-Hee
    Waked, Imam
    Shao, Yu Yun
    Tai, Wai Meng David
    Breder, Valeriy
    Alolayan, Ashwaq
    Ganguly, Sandip
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618
  • [40] Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
    Welland, Sabrina
    Leyh, Catherine
    Finkelmeier, Fabian
    Jefremow, Andre
    Shmanko, Kateryna
    Gonzalez-Carmona, Maria A.
    Kandulski, Arne
    Jeliazkova, Petia
    Best, Jan
    Fruendt, Thorben W.
    Djanani, Angela
    Pangerl, Maria
    Maieron, Andreas
    Greil, Richard
    Fricke, Christina
    Sookthai, Disorn
    Guenther, Rainer
    Schmiderer, Andreas
    Wege, Henning
    Venerito, Marino
    Ehmer, Ursula
    Mueller, Martina
    Strassburg, Christian P.
    Weinmann, Arndt
    Siebler, Jurgen
    Waidmann, Oliver
    Lange, Christian M.
    Saborowski, Anna
    Vogel, Arndt
    LIVER CANCER, 2022, 11 (03) : 219 - 232